PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1768086
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1768086
North America Vision Care Market is estimated to be valued at USD 7.03 Bn in 2025 and is expected to reach USD 9.57 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.5% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 7.03 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 4.50% | 2032 Value Projection: | USD 9.57 Bn |
The prevention and treatment of various eye disorders, such as poor eye sight, is referred to as vision care. To restore eye sight, a variety of vision care items are employed, including prescription lenses, frames, contact lenses, non-prescription sunglasses, reading glasses, and contact lens solutions. Over the course of the projected period, rising cataract prevalence is anticipated to drive market expansion in North America. The market for eye care in North America is also anticipated to develop over the projected period as contact lens use among youngsters increases.
The market for vision care in North America is expected to grow as a result of an aging population and a rise in the proportion of residents who suffer from myopia, hyperopia, or other optical diseases. The increasing usage of eyeglasses as a fashion accessory is one of the major trends in vision care. Eye care, eye disorders, and vision care are all included in the broad topic of vision care. It is one of the fastest-growing sectors in the modern world. Untreated eye conditions such as glaucoma, corneal opacities, cataracts, diabetic retinopathy, trachoma, refractive error, and presbyopia affect the vision of millions of people today. These conditions and illnesses can all be treated with surgery, glasses, and contact lenses. The elderly population has revived the demand for vision care.
For example, in November 2021, the first U.S. FDA-approved autonomous artificial intelligence system was created for detecting diabetic retinopathy, the first FDA-approved gene therapy for an inherited disease targeted a retinal degeneration, and key discoveries in neural information processing were initially made in the visual system.